According to Pedro Abreu, clinical oncologist at Oncoclínicas Rio de Janeiro, at the 2021 American Society of Clinical Oncology (ASCO) annual meeting, Motzer et al. reported results of the study’s secondary endpoints comparing the impact of lenvatinib + pembrolizumab or everolimus versus sunitinib on health-related quality of life.
“What was shown was that the combination lenvatinib + pembrolizumab was equal to or superior to sunitinib in both symptom control and quality of life. The combination lenvatinib + everolimus was not superior to sunitinib in terms of quality of life”, he describes.
In his opinion, CLEAR is a study that puts yet another first-line combination treatment option in advanced kidney cancer: “This study specifically focused on quality of life and was able to aggregate more information about the impacts of treatment under that domain. Although it is important to emphasize that although there are more and more studies that analyze the quality of life, we still need to advance further in this field.”x’
Go to our website and read the full article with all the details of this study and others that are part of our coverage of ASCO 2021.